Certara, Inc. (CERT)
After hours:
| Previous Close | 26.75 |
| Open | 26.46 |
| Bid | 24.55 x 3200 |
| Ask | 26.44 x 800 |
| Day's Range | 25.46 - 26.74 |
| 52 Week Range | 23.75 - 45.48 |
| Volume | |
| Avg. Volume | 1,027,109 |
| Market Cap | 4.083B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.40 |
| Earnings Date | Mar. 02, 2022 - Mar. 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.20 |
- Zacks
Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?
Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- Zacks
Can Certara, Inc. (CERT) Climb 35% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Certara, Inc. (CERT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- GlobeNewswire
Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions
FDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and officesPRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and expanded its licenses of Certara’s proprietary biosimulation software, with more than 400 user licenses of Simcyp and Phoenix software. In total, there are 12 divisions and offices of the FDA using Certara’s so
